Capital Research Global Investors
DNLI icon

Capital Research Global Investors’s Denali Therapeutics DNLI Stock Holding History

Capital Research Global Investors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.3M Sell
2,514,588
-1,214,656
-33% -$24.2M 0.01% 359
2025
Q4 		$61.6M Sell
3,729,244
-1,031,614
-22% -$17.4M 0.01% 338
2025
Q3 		$69.1M Buy
4,760,858
+10,279
+0.2% +$148K 0.01% 324
2025
Q2 		$66.5M Sell
4,750,579
-14,558
-0.3% -$205K 0.01% 322
2025
Q1 		$64.8M Sell
4,765,137
-712,074
-13% -$13.6M 0.01% 339
2024
Q4 		$112M Sell
5,477,211
-2,431,903
-31% -$62.3M 0.02% 291
2024
Q3 		$230M Buy
7,909,114
+782,581
+11% +$19.4M 0.05% 201
2024
Q2 		$165M Buy
7,126,533
+1,076,576
+18% +$20.7M 0.04% 240
2024
Q1 		$124M Buy
6,049,957
+3,140,429
+108% +$59M 0.03% 271
2023
Q4 		$62.4M Buy
2,909,528
+29,205
+1% +$578K 0.02% 307
2023
Q3 		$59.4M Buy
2,880,323
+42,671
+2% +$1.08M 0.02% 315
2023
Q2 		$83.7M Buy
2,837,652
+368,828
+15% +$10.4M 0.02% 291
2023
Q1 		$56.9M Buy
2,468,824
+208,182
+9% +$5.73M 0.02% 316
2022
Q4 		$62.9M Buy
2,260,642
+2,172,875
+2,476% +$64.7M 0.02% 311
2022
Q3 		$2.65M Buy
+87,767
New +$2.85M ﹤0.01% 416

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Research Global Investors's DNLI Position: Q1 2026 in Review

Capital Research Global Investors reduced its Denali Therapeutics (DNLI) stake by 33% in Q1 2026, selling an estimated $24.2M and leaving 2,514,588 shares worth $48.3M. The position accounts for 0.01% of the portfolio, ranked #359.

Capital Research Global Investors first reported a position in DNLI in Q3 2022 and has held it in 15 quarters since. The position peaked at $230M in Q3 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Capital Research Global Investors held 2,514,588 shares of Denali Therapeutics worth $48.3M as of Q1 2026.
  • Capital Research Global Investors sold 1,214,656 Denali Therapeutics shares in Q1 2026, an estimated $24.2M.
  • Denali Therapeutics made up 0.01% of Capital Research Global Investors's portfolio in Q1 2026, its #359 holding.
  • Capital Research Global Investors first reported a position in Denali Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Capital Research Global Investors's Denali Therapeutics position peaked at $230M in Q3 2024.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.